Date: Friday, April 26, 2019
Time: 11 am EDT
Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes. Often, patient factors and insights are not considered or discovered until the later phases of drug development when dose form, dose strength, and route of administration are already decided. There is tremendous potential benefit of equipping formulators and other scientists with patient insights earlier in the development process so that the drug product can be designed to address the specific needs of target patient populations.
During this webcast experts will discuss the current state of patient-focused drug design, including key learnings from real world case studies, barriers faced by scientists to incorporate patient-focused drug design principles, and opportunities for drug developers to launch better treatments for patients.
Matt Burke, PhD
Head of Drug Delivery
Rubi Burlage, PhD
Executive Director, Sterile Formulation Sciences
Cornell Stamoran, PhD
Vice President, Strategy & Govt. Affairs, Founder & Co-Chair
Catalent Applied Drug Delivery Institute